J&J seeks DCGI's permission for phase-3 clinical trial of its single-dose Covid-19 vaccine

“We have submitted an application to the Drugs Controller General of India (DCGI) requesting approval to conduct a bridging clinical study of our single-dose Janssen COVID-19 vaccine candidate in India to comply with local regulations,” the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3apSzNE
via IFTTT